Genmab — April 2020
-
Jan har bekræftet at flere er parate til 50/50 partner aftale. Hvorfor lytter du ikke til Q/A efter årsregnskabet i februar
-
Februar 2020
-
19.02.2020 www.genmab.com, Archived Event Listen to webcast
-
Han dog aldrig været så konkret som her https://ir.genmab.com/events-and-presentations#tab2
-
Never mind i ikke mener Jan er specielt troværdig. Men siden han blev CEO, har Genmab nok været den bedste C20 aktie, så noget må har da været rigtigt...
-
OK lad so se hvad der sker frem til halvårsskiftet
-
-
@Stockbull. Mange tak for link til Lars Tvede. For de af der ikke har lyttet til det, kan det på alle måder anbefales.
-
God morgen.
-
Citi opens 'positive Catalyst Watch' on Genmab Citi analyst Peter Verdult opened a "positive Catalyst Watch" on Genmab and keeps a Buy rating on the shares. The analyst expects that the recommended Phase II dose for Genmab's bispecific blood cancer asset, epcoritamab, along with a partnership deal, could be delivered by mid-year.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind